Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. Written by Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. The median estimate. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Making the world smarter, happier, and richer. If they invent a miracle treatment for a condition, the money will find its way to the stock. Start trading Options with Saxo today. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. 2023 InvestorPlace Media, LLC. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. The Motley Fool has a disclosure policy. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Bharat Biotech has a history of successful vaccine commercialization in South Asia. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Copy and paste multiple symbols separated by spaces. Investors should worry about companies with no revenue even under the best of circumstances. Keith Speights owns shares of Pfizer. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. The company stated that it will pursue a path to file for full FDA approval of Covaxin. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. The Motley Fool->. The biotech stock promptly crashed by more than 30%. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Learn More. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Keith Speights has no position in any of the stocks mentioned. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Type a symbol or company name. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Other than an emphasis on cell therapies, the companies had almost nothing in common. The Motley Fool recommends Moderna Inc. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Histogenics itself highlights the risks involved in small-cap biotech. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. The chances of anything more are small but the rewards could be huge. 1125 N. Charles St, Baltimore, MD 21201. From a near-term standpoint, there are two key risks. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. That's right -- they think these 10 stocks are even better buys. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Do Not Sell My Personal Information (CA Residents Only). The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. *Average returns of all recommendations since inception. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." See disclosure here. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. That doesnt mean success is guaranteed. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Maybe. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Copy and paste multiple symbols separated by spaces. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Ocugen estimates the drug could have as many as 63,000 potential patients. Copyright 2023 InvestorPlace Media, LLC. The $25 million private placement executed before the merger brought in much-needed cash. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Type a symbol or company name. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Companies will inevitably be optimistic about their prospects for success (at least publicly). Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. Conditions have only become worse since that time. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. It means that institutional investors focused on the sector largely have passed on the pipeline. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. The equity has experienced a continual decline for years. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? 1125 N. Charles St, Baltimore, MD 21201. The stock had gained some traction after they announced the Ocugen merger in April. Like other life sciences companies involved in Covid-19 vaccine. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor.
How To Open Petra Mints 2020, How To Use Verifly App American Airlines, The One With Ross And Monica's Cousin Explained, Gm Financial Change Payment Date, Mark Palios Family, Articles O
How To Open Petra Mints 2020, How To Use Verifly App American Airlines, The One With Ross And Monica's Cousin Explained, Gm Financial Change Payment Date, Mark Palios Family, Articles O